Surrozen : Corporate Presentation March 22, 2023

Targeted Regeneration

March 22, 2023

Corporate Update

Legal Disclaimers

Forward-lookingstatements. This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward- looking statements generally are accompanied by words such as "will," "expect," "continue," "plan," "target," "potential," "next steps," "milestone," "future," "opportunities," "key endpoints," "near term," "outlook," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen's discovery, research and development activities, in particular its development plans for its product candidates SZN-1326,SZN-043,SZN-413 and potential future candidates, including anticipated clinical development timelines and availability of data, the potential for such product candidates to be used to treat human disease, expected reduction in operating expenses in 2023 and extension of cash runway into the second half of 2024. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of Surrozen. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to SZN-1326,SZN-043,SZN-413 and potential future drug candidates; Surrozen's ability to fund its clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen's ability to identify, develop and commercialize drug candidates; Surrozen's ability to successfully complete preclinical and clinical studies for SZN-1326,SZN-043,SZN-413, or other future product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and those factors discussed in Surrozen's Annual Report on Form 10-K for the year ended December 31, 2021 and Form 10-Q for the quarter ended September 30, 2022, primarily under the heading "Risk Factors," and other documents Surrozen has filed, or will file, with the Securities and Exchange Commission. If any of these risks materialize or the underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen's expectations, plans, or forecasts of future events and views as of the date of this presentation. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen's assessments of any date after the date of this presentation. Accordingly, undue reliance should not be placed upon the forward- looking statements.

© 2023 Surrozen, Inc.	2

Surrozen - Leader in Wnt Biology

Building for the Future with Innovative Pipeline in Wnt Pathway Modulation

First-in-Class	Novel Targeted
Best-in-Class	Regeneration

Transform Patient

Outcomes

Selectively target Wnt pathway to harness body's own repair mechanism Robust proof of mechanism / biology

Demonstrated preclinical POC for several programs

SZN-043: Novel hepatocyte targeted Wnt agonist in development for SAH Well tolerated in Ph1a

Enrolled first patient in chronic liver disease trial; expect data YE'23

Initiate Ph 1b in SAH in '24; expect data in 2H'24; potential fast path to approval

SZN-1326: Potential best in class, first in class epithelial barrier repair agent Re-initiating Phase 1a in HV's with MABEL dosing strategy; Expect data by YE'23 Initiate Ph 1b in UC patients in 2024; expect data in 2H'24

Partnered with BI for retinopathy research program

Expect to reduce expenses ~15% in 2023, extending cash runway into 2H'24 Focused research efforts on ophthalmology programs: lacrimal and cornea

© 2023 Surrozen, Inc.

3

Surrozen Science Addresses Multiple Barriers

Paving the Way to Targeted Antibody Regeneration

Characteristics of Surrozen Platform

Selectivity: Target specific Fzd or cell surface receptors

Potency: Confer potency through multivalent binding

Biology: Mimic normal physiologic responses

Manufacturing: Manufacturable leveraging industry standard antibody methods with high yields

Prominent Role in Wnt Biology Breakthroughs

Surrogate Wnt agonists that phenocopy canonical Wnt and - catenin signaling

Development of Potent, Selective Surrogate Wnt Molecules and Their Application in Defining Frizzled Requirements

Tissue-targetedR-spondin mimetics for liver regeneration

cmgh

Robust Colonic Epithelial Regeneration and Amelioration of Colitis Via FZD-Specific Activation of Wnt Signaling

tvst an ARVO Journal

SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy

© 2023 Surrozen, Inc.

4

Wnt Biology and Regeneration Underpins a Compelling R&D Pipeline

Lead Programs		Indication(s)	Research	Preclinical	Phase 1	Phase 2	Phase 3	Partnerships Status
SZN-043		Severe Alcoholic							Enrolled first patient
							in chronic liver disease
		Hepatitis							trial
SZN-1326		Moderate to							Plans to re-initiate
	Severe IBD							Ph 1a in mid-2023
SZN-413		Retinopathies

Research Programs

Tissue		Indications	Discovery	Proof of Concept	Lead Candidate/s
Lacrimal Gland		Severe Dry Eye (Sjögren's)
Cornea		Fuchs' Dystrophy

© 2023 Surrozen, Inc.	5